Utilizing TRIPS Flexibilities for Public Health Protection Through South-South Regional Frameworks
(2004; 110 pages) [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoTHE SOUTH CENTRE
Ver el documentoPREFACE
Ver el documentoABBREVIATIONS
Ver el documentoEXECUTIVE SUMMARY
Abrir esta carpeta y ver su contenidoI. INTRODUCTION
Abrir esta carpeta y ver su contenidoII. INTELLECTUAL PROPERTY AND ACCESS TO ESSENTIAL MEDICINES IN DEVELOPING COUNTRIES
Cerrar esta carpetaIII. CONSTRAINTS ON NATIONAL EFFORTS TO IMPLEMENT TRIPS FLEXIBILITIES FOR PUBLIC HEALTH PURPOSES
Ver el documentoIII.1 Lack of Technical Expertise to Incorporate and Implement TRIPS Flexibilities in National Law and Policy
Ver el documentoIII.2 Insufficient Domestic Research and Manufacturing Capacities in the Pharmaceutical Sector
Ver el documentoIII.3 Insufficient Technical and Infrastructural Capacities for Medicines Regulation
Ver el documentoIII.4 Difficulties in Establishing Efficient Pharmaceutical Management and Procurement Systems
Ver el documentoIII.5 Bilateral and other TRIPS-plus Pressures
Ver el documentoIII.6 Difficulties in Tackling Anti-Competitive Practices and Abuse of Intellectual Property Rights
Abrir esta carpeta y ver su contenidoIV. OVERCOMING CONSTRAINTS IN THE USE OF TRIPS FLEXIBILITIES THROUGH SOUTH-SOUTH REGIONAL FRAMEWORKS
Abrir esta carpeta y ver su contenidoV. CONCLUSIONS AND RECOMMENDATIONS
Ver el documentoBIBLIOGRAPHY
Ver el documentoBACK COVER
 

III. CONSTRAINTS ON NATIONAL EFFORTS TO IMPLEMENT TRIPS FLEXIBILITIES FOR PUBLIC HEALTH PURPOSES

Incorporating the public health-related TRIPS flexibilities into national law and policy is necessary but not sufficient to deal with the patent-related obstacles to improving access to medicines. There are therefore two levels of constraints that need to be addressed if developing countries are effectively to use TRIPS flexibilities for public health purposes.

The first level relates to constraints associated with the incorporation and general implementation of the TRIPS flexibilities themselves. The second level relates to constraints in the framing and implementation of supporting legal and policy measures such as those concerning local innovation and production of pharmaceuticals. For example, legal and policy measures need to be introduced to guarantee availability of alternative sources of medicines, either through local production or through importation; to assure the quality of the medicines; to ensure expedited registration of essential generics; and to ensure cost effectiveness of the resources spent in the procurement of medical supplies. The constraints in implementing these secondary legal and policy measures at the national level have the effect of inhibiting the effective use of the TRIPS flexibilities.

The main constraints at the second level include the lack of domestic pharmaceutical research and manufacturing capacities; insufficient technical and infrastructural capacities for medicines regulation; difficulties in establishing efficient pharmaceutical management and procurement systems; bilateral and other political pressures against the use of TRIPS flexibilities; lack of capacity to address anti-competitive practices and abuse of patent rights; and difficulties in accessing pricing and patent status information.

Ir a la sección anterior
Ir a la siguiente sección
 
 
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019